Tandem Diabetes

Tandem did $1.0 billion in revenue and still ran at a -18.5% operating margin.

If you own TNDM, you are betting losses shrink before pump demand slips again.

tndm

healthcare · medical devices small cap updated feb 6, 2026
$20.20
market cap ~$1B · 52-week range $10–$24
xvary composite: 28 / 100 · weak
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
Tandem sells insulin pumps and software that help people with diabetes dose insulin all day.
how it gets paid
Last year Tandem Diabetes made $1.0B in revenue.
why it's growing
Revenue grew 249.4% last year. Revenue rose 3% vs. prior year and gross margin hit 57.7%.
what just happened
Tandem posted $290M in quarterly revenue and EPS of -$0.01, far better than the -$0.69 estimate.
At a glance
C++ balance sheet — some cracks in the foundation
20/100 earnings predictability — expect surprises
22.0% return on capital — every dollar works hard here
xvary composite: 28/100 — weak
-$0.60 fy2027 eps est
What they do
Tandem sells insulin pumps and software that help people with diabetes dose insulin all day.
This business sits on your body, not just your phone. Once your pump, glucose monitor, and dosing software are working together, switching gets personal and annoying. Tandem already does about $1.0 billion in annual revenue, and its latest gross margin was 57.7%, which means the product still has pricing power even while expenses are eating the profit.
medtech small-cap device-sales diabetes-tech turnaround
How they make money
$1.0B annual revenue · their business grew +249.4% last year
total revenue
$1.0B
+249.4%
The products that matter
core insulin pump hardware
t:slim X2 insulin pump
$1.0B revenue · 100% of sales
it's the whole business today, generating 100% of the company's $1.0B in annual sales. that's focus. it's also concentration risk with no second segment to catch a miss.
core
automated insulin delivery software
control-IQ technology
software layer on the $1.0B platform
this is the stickier part of the story. it sits on top of the same platform that drives $1.0B in revenue and gives users one more reason not to switch.
switching cost
new compact pump hardware
mobi insulin pump
new product · diversification attempt
mobi matters because the current setup is too concentrated. when one platform still accounts for 100% of $1.0B in sales, every new product has to do more than look interesting.
catalyst watch
Key numbers
18.5%
operating margin
Operating margin → money left after running the business → so what: Tandem is still losing about $0.19 on every $1 of sales.
$32
18-month target
18-month target → a forecast for where shares may trade in about a year and a half → so what: that is 58% above $20.2, but only if losses keep shrinking.
$2.0B
2029 revenue
2029 revenue estimate → expected annual sales a few years out → so what: the model needs revenue to roughly double from $1.0 billion for the bull case to work.
57.7%
gross margin
Gross margin → what is left after making the product → so what: the pump economics are decent, but overhead is swallowing the benefit.
Financial health
C++
strength
  • balance sheet grade C++ — below average — limited financial resources
  • risk rank 5 — safer than 5% of stocks
  • price stability 5 / 100
  • long-term debt $310M (18% of capital)
  • net profit margin 10.0% — keeps 10 cents of every dollar in revenue
  • return on equity 62% — $0.62 profit for every $1 investors have put in
C++ — return on equity looks solid but balance sheet grade needs watching.
Total return vs. market

You invested $10,000 in TNDM 3 years ago → it's now worth $5,130.

The index would have given you $14,770.

same period. same starting point. TNDM trailed the market by $9,640.

source: institutional data · total return
What just happened
beat estimates
Tandem posted $290M in quarterly revenue and EPS of -$0.01, far better than the -$0.69 estimate.
Revenue rose 3% vs. prior year and gross margin hit 57.7%. The quarter looked better than feared, but the full-year picture still shows margin pressure and a 2025 EPS loss of $2.15.
$290M
revenue
$0.01
eps
57.7%
gross margin
the number that mattered
The key number was EPS of -$0.01 versus a -$0.69 estimate because it proved the business can still surprise upward even while full-year losses remain ugly.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

the #1 risk is pump demand slowing on the t:slim platform.

!
high
single-platform concentration
100% of revenue comes from one pump platform. if demand slips, there is no second segment to smooth the results.
exposes 100% of the current $1.0B revenue base
!
high
expense growth outrunning demand
SG&A rose as tandem built out sales infrastructure. that spending may pay off later, but right now it is one reason a $290M quarter still produced a -0.2% net margin.
keeps profitability delayed even if revenue stays around $1B
∘
med
weaker financial flexibility
a C++ balance sheet and $310M in long-term debt mean execution mistakes matter more here than they would at a cash-rich large-cap medtech company.
less room for a disappointing launch or slower pump uptake
∘
med
institutional sponsorship fading
institutions were net sellers for 2 straight quarters, with 114 buyers versus 153 sellers in 3q2025. that is not a verdict. it is also not support.
weaker sponsorship can amplify volatility in a 5 / 100 stability stock
30,000 q3 pump shipments versus 31,000 a year earlier does not look dramatic on its own. paired with 100% revenue concentration and a -0.2% quarterly net margin, it becomes the whole story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
pump shipments
q3 2025 shipments fell to 30,000 from 31,000 a year earlier. if that becomes a pattern, the one-product model stops looking focused and starts looking exposed.
trend
revenue vs. profit gap
revenue likely reached $1.0B for 2025, yet fy2026 EPS is still expected at -$1.00. you want that gap narrowing, not settling in.
risk
sales infrastructure payback
SG&A has been the pressure point. if higher spending does not show up in stronger unit demand, the margin story gets harder to defend.
calendar
next confirmation on full-year results
the current read is roughly $1.0B in 2025 revenue with pressured profitability. the next print needs to show whether demand softened briefly or something deeper is happening.
Analyst rankings
short-term outlook
below average
momentum score 4 — in human-speak, analysts think this is more likely to lag than lead over the next 12 months.
risk profile
high risk
stability score 5 — this stock has historically been more fragile than 95% of the market.
chart momentum
average
technical score 3 — no clear upside signal from the tape right now.
earnings predictability
20 / 100
low predictability means quarterly results can move around fast. if you own it, expect surprises.
source: institutional data
Institutional activity

institutions have been net selling for 2 consecutive quarters — 114 buyers vs. 153 sellers in 3q2025. total institutional holdings: 75.6M shares. net selling for 2 quarters.

source: institutional data · 1q2025-3q2025
source: institutional data
Price targets
3-5 year target range
$12 $51
$20 current price
$32 target midpoint · +58% from current · 3-5yr high: $51
source: institutional data · analyst targets

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
TNDM
xvary deep dive
tndm
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it